X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Novel Purification Means For Protein Drug Manufacturing

Content Team by Content Team
9th March 2023
in Drug Development, Featured, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

In a recent study, researchers at the Massachusetts Institute of Technology (MIT) have come up with a new purification approach to reduce the cost of making protein drugs. So as to isolate proteins from a bioreactor rapidly and cheaply, the engineers utilized bioconjugate-functionalized nanoparticles.

Manufacturing Biologics by way of Isolating Protein

In huge bioreactors, living cells like yeast create biologics such as antibodies as well as other protein-based medications.

The proteins must be separated from the reactor once they have been produced. The most common approach is chromatography. It sorts proteins according to their size. Yet, this process can account for up to 50% of total manufacturing costs.

Protein crystallization is deemed too slow for industrial usage and does not operate effectively at low protein concentrations. To solve these challenges, Varanasi’s lab chose nanoparticle adaptation so that they might boost protein concentration at the surface locally. It could also serve as a template for the proteins to align the way they should and produce crystals.

According to Kripa Varanasi, a mechanical engineering professor at MIT and also the study’s senior author, the nanoparticles work as templates when it comes to boosting protein crystal formation at concentrations which are low.

Bioconjugate nanoparticles’ protein crystallization

Varanasi and his colleagues, therefore, tried an alternative technique as far as focusing on protein crystallization goes.

The researchers showed their method using lysozyme, an enzyme with well-studied crystallisation properties, and insulin.

To achieve the desired surface, the researchers coated gold nanoparticles along with the bioconjugates maleimide (MAL) as well as N-hydroxysuccinimide ester (NHS). According to scientists, these happen to be routinely utilised for tagging proteins for research or linking protein medicines to drug delivery nanoparticles.

When protein solutions are presented to these coated nanoparticles, the proteins aggregate at the surface and bind to the bioconjugates, according to the researchers. Additionally, the bioconjugates force the proteins to align in a precise direction, forming a frame for additional proteins to join the crystal.

Novel purification method findings

The coated particles reduced the induction time, or how long it takes for crystals to form, by seven times.

A threefold rise in the nucleation rate, or how quickly crystals grow once they start to form, was also noted.

According to Caroline McCue, the study’s primary author, even at low protein concentrations, a lot more crystals are developed when using these bioconjugate-functionalized nanoparticles. Because these bioconjugates provide a particular place for the proteins to bind, the functionalized nanoparticles significantly shorten the induction time. As the proteins are aligned, they may form a crystal more quickly.

The results showed that when the proteins were exposed to bioconjugate-coated nanoparticles, they crystallised much faster than when they were exposed to plain nanoparticles or no nanoparticles.

Proteins crystal analysis by way of using machine learning

Also, the group analysed thousands of crystal photos using machine learning. According to McCue, they needed a sizable dataset to be able to assess whether their strategy improved the induction time as well as the crystallisation nucleation rate. Machine learning is the best method for being able to tell when crystals are growing in each image without having to go through or manually count each one when there are so many photographs to examine.

The MIT team is currently demonstrating that the method can be used to produce monoclonal antibodies, vaccines, as well as other valuable proteins while scaling up the procedure for use in an industrial bioreactor.

This is a general strategy that may also be applied to other systems. One can compel this process to occur by adding the proper bioconjugates if one is aware of the protein structure that’s been sought to crystallize, according to Varanasi.

The research has been supported in part by a National Science Foundation Graduate Research Fellowship and the Gates Foundation.

The findings have been reported in Applied Materials & Interfaces by the ACS.

Previous Post

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

Next Post

Pharma Responds To The Statutory Scheme Surge By The UK

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Pharma Responds To The Statutory Scheme Surge By The UK

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In